CredoScientia - Bibliothèque

Imaging-defined complete response to immune checkpoint inhibitors predicts durable survival in advanced hepatocellular carcinoma.

BACKGROUND: Immune checkpoint inhibitors (ICIs) have revolutionized advanced hepatocellular carcinoma (HCC) treatment, yet complete responses (CRs) remain rare, and their long-term outcomes are poorly…

Thérapies de Conversion

Shao, Y., Yuan, J., Liu, Y., & Wang, F. (2025). Imaging-defined complete response to immune checkpoint inhibitors predicts durable survival in advanced hepatocellular carcinoma.. Front Oncol, 15, 1687449. https://doi.org/10.3389/fonc.2025.1687449

01/01/2025 Lire →

Case Report: Successful Surgical Resection of PVTT Vp4 Hepatocellular Carcinoma Following Hepatic Arterial Infusion Chemotherapy Combined with Cadonilimab Plus Donafenib.

OBJECTIVE: To evaluate the potential and efficacy of hepatic artery infusion chemotherapy combined with the PD-1/CTLA-4 bispecific antibody cadonilimab and the multi-kinase inhibitor donafenib in conv…

Thérapies de Conversion

Chen, S., Wei, Y., Liao, X., Yang, C., Zhu, G., Han, C., Su, H., & Peng, T. (2025). Case Report: Successful Surgical Resection of PVTT Vp4 Hepatocellular Carcinoma Following Hepatic Arterial Infusion Chemotherapy Combined with Cadonilimab Plus Donafenib.. Pharmgenomics Pers Med, 18, 279-286. https://doi.org/10.2147/PGPM.S555061

01/01/2025 Lire →

Correction: Immunotherapy in conversion therapy for gastric cancer: current status, progress, and challenges.

[This corrects the article DOI: 10.3389/fonc.2025.1637657.].

Thérapies de Conversion

Su, Y., Zhang, X., & Deng, W. (2025). Correction: Immunotherapy in conversion therapy for gastric cancer: current status, progress, and challenges.. Front Oncol, 15, 1730862. https://doi.org/10.3389/fonc.2025.1730862

01/01/2025 Lire →

Correction: Conversion therapy with TACE, TKIs, and ICIs for unresectable BCLC stage B and C hepatocellular carcinoma.

[This corrects the article DOI: 10.3389/fimmu.2025.1451965.].

Thérapies de Conversion

Wang, Z., Zhang, C., Yin, J., & Li, N. (2025). Correction: Conversion therapy with TACE, TKIs, and ICIs for unresectable BCLC stage B and C hepatocellular carcinoma.. Front Immunol, 16, 1647890. https://doi.org/10.3389/fimmu.2025.1647890

01/01/2025 Lire →

Spontaneous Rupture of Hepatocellular Carcinoma: Pathogenesis, Clinical Management, Prognostic Factors, and Future Directions.

Spontaneous rupture of hepatocellular carcinoma (srHCC) is a life-threatening complication with complex pathophysiology and heterogeneous clinical presentations. This review aims to provide an up-to-d…

Thérapies de Conversion

Cheng, Y., Ye, F., & Chen, Y. (2025). Spontaneous Rupture of Hepatocellular Carcinoma: Pathogenesis, Clinical Management, Prognostic Factors, and Future Directions.. J Hepatocell Carcinoma, 12, 2421-2428. https://doi.org/10.2147/JHC.S540510

01/01/2025 Lire →

Pathological complete response to conversion therapy for lung adenocarcinoma with brain metastasis: a case report.

Lung cancer is the leading cause of cancer mortality worldwide. Fortunately, the advent of precision medicine, which includes targeted therapy and immunotherapy, has significantly improved the surviva…

Thérapies de Conversion

Ran, X., Luo, T., Xiong, J., & Fu, M. (2025). Pathological complete response to conversion therapy for lung adenocarcinoma with brain metastasis: a case report.. Front Oncol, 15, 1625918. https://doi.org/10.3389/fonc.2025.1625918

01/01/2025 Lire →

A Novel Quadruple Conversion Therapy: Converting Initially Unresectable Hepatocellular Carcinoma to Resectable with pTAE-HAIC, Tyrosine Kinase Inhibitors, and Anti-PD-1 Antibodies.

PURPOSE: The aim of this study was to evaluate the potential of partial transcatheter arterial embolization (pTAE)-hepatic artery infusion chemotherapy (HAIC) in combination with tyrosine kinase inhib…

Thérapies de Conversion

Xiao, J., Li, Q., Zheng, W., Liao, K., Yu, Q., Huang, R., & Zhou, R. (2025). A Novel Quadruple Conversion Therapy: Converting Initially Unresectable Hepatocellular Carcinoma to Resectable with pTAE-HAIC, Tyrosine Kinase Inhibitors, and Anti-PD-1 Antibodies.. J Hepatocell Carcinoma, 12, 1807-1819. https://doi.org/10.2147/JHC.S523755

01/01/2025 Lire →

Conversion study of hepatocellular carcinoma using HAIC combined with lenvatinib and PD-1/L1 immunotherapy under the guidance of BCLC staging.

OBJECTIVE: This study aimed to assess the efficacy and safety of hepatic arterial infusion chemotherapy (HAIC) combined with lenvatinib and immunotherapy and explore its potential as a conversion trea…

Thérapies de Conversion

Zhang, W., Zhao, X., Gao, W., Si, T., Zou, Q., Yang, X., Xing, W., & Yu, H. (2025). Conversion study of hepatocellular carcinoma using HAIC combined with lenvatinib and PD-1/L1 immunotherapy under the guidance of BCLC staging.. Front Immunol, 16, 1596864. https://doi.org/10.3389/fimmu.2025.1596864

01/01/2025 Lire →

Understanding harms associated with gender identity conversion efforts among transgender and nonbinary individuals: The role of preexisting mental well-being.

Affirmation of gender identity is critical for the mental health and overall well-being of transgender and nonbinary (TNB) persons. Gender identity conversion efforts (GICE), an outlawed practice for…

Thérapies de Conversion

Mammadli, T., Call, J., Whitfield, D. L., Holloway, B. T., & Walls, N. E. (2025). Understanding harms associated with gender identity conversion efforts among transgender and nonbinary individuals: The role of preexisting mental well-being.. Int J Transgend Health, 26(1), 157-179. https://doi.org/10.1080/26895269.2024.2333531

01/01/2025 Lire →

Adaptive transition decisions and identity exploration among transgender and nonbinary persons exposed to gender identity conversion efforts.

INTRODUCTION: Transgender and nonbinary (TNB) persons' healthcare experiences and related transition decisions have received increasing attention in recent years. Growing literature indicates gender n…

Thérapies de Conversion

Mammadli, T., Call, J., Holloway, B. T., Whitfield, D. L., & Walls, N. E. (2025). Adaptive transition decisions and identity exploration among transgender and nonbinary persons exposed to gender identity conversion efforts.. Int J Transgend Health, 26(1), 198-214. https://doi.org/10.1080/26895269.2024.2415681

01/01/2025 Lire →

Prognosis predictors of hepatocellular carcinoma after hepatectomy following conversion therapy.

BACKGROUND: Hepatectomy is the optimal treatment for less than 20 % patients with hepatocellular carcinoma (HCC). A combination of hepatic artery infusion chemotherapy and systemic therapy-based conve…

Thérapies de Conversion

Liu, S., Wu, Z., Wang, C., Qiao, L., Huang, Z., Yuan, Y., Zou, R., He, W., Li, B., Yuan, Y., & Qiu, J. (2025). Prognosis predictors of hepatocellular carcinoma after hepatectomy following conversion therapy.. Eur J Surg Oncol, 51(1), 109375. https://doi.org/10.1016/j.ejso.2024.109375

01/01/2025 Lire →

Prognostic Evaluation of Conversion Therapy following Hepatic Arterial Infusion Chemotherapy or Immunotherapy in Patients with Advanced or Transarterial Chemoembolization Unsuitable Intermediate-Stage Hepatocellular Carcinoma: A Retrospective Cohort Study

INTRODUCTION: Patients with advanced-stage or intermediate-stage hepatocellular carcinoma (HCC) unsuitable for transarterial chemoembolization (TACE) had poor prognoses. Recent advancements in hepatic…

Thérapies de Conversion

Kuo, L. F., Liu, W. C., Li, M. F., Huang, F. H., Chou, C. K., Chen, T. H., Tsai, Y. T., Hsu, P. I., Li, C. J., Wu, I. T., & Tsai, K. F. (2025). Prognostic Evaluation of Conversion Therapy following Hepatic Arterial Infusion Chemotherapy or Immunotherapy in Patients with Advanced or Transarterial Chemoembolization Unsuitable Intermediate-Stage Hepatocellular Carcinoma: A Retrospective Cohort Study. Oncology, 103(7), 549-561. https://doi.org/10.1159/000542291

01/01/2025 Lire →